Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: A one-centre experience

European Journal of Cancer Care

Volumn 14, Issue 2, 2005, Pages 151-154

  Rocha Lima, A P ^a   Del Giglio, A ^a,b  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b NONE   (Brazil)

Author keywords

Crossover studies; Fluorouracil; Patient satisfaction; Prospective studies; Tegafur; Uracil

Indexed keywords

ANTIINFECTIVE AGENT; FLUOROURACIL; FOLINIC ACID; URACIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CENTER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE COURSE; FEMALE; HOME CARE; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; SIDE EFFECT; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; CROSS-OVER STUDIES; FEMALE; FLUOROURACIL; HUMANS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; TEGAFUR; URACIL;

EID: 18544387574     PISSN: 09615423     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2005.00531.x     Document Type: Article

References (13)

1. Borner M., Schoffski P., de Wit R., Caponigro F., Comella G., Sulkes A., Greim G., Peters G.J., van der Born K., Vanders J., de Boer R.F., Martin C. & Fumoleau P. (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. European Journal of Cancer 38, 349-358.
2. Common Toxicity Criteria (1993) National Institutes of Health, Cancer Therapy Evaluation Program, Division of Cancer Treatment, Bethesda, MD, USA.
3. Doroshaw J.H., Multhauf P., Leong L., Margolin K., Litchfield T., Akman S., Carr B., Bertrand M., Goldberg D. & Blayney D. (1990) Prospective randomized comparison of fluorouracil and high dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. Journal of Clinical Oncology 8, 491-493.
4. Erlichman C., Fine S., Wong A. & Elhakim T. (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. Journal of Clinical Oncology 6, 469-472.
5. Greenlee R.T., Hill-Harmon M.B., Murray T. & Thun M. (2001) Cancer statistics, 2001. CA: A Cancer Journal for Clinicians 51, 15-36.
6. Hoff P.M., Ansari R., Batist G., Cox J., Kocha W., Kuperminc M., Maroun J., Walde D., Weaver C., Harrison E., Burger H.U., Osterwalder B., Wong A.O. & Wong R. (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. Journal of Clinical Oncology 19, 2282-2292.
7. Hoff P.M., Royce M., Medgyesy D., Brito R. & Pazdur R. (1999) Oral fluoropyrimidines. Seminars in Oncology 26, 640-646.
8. Liu G., Franssen E., Fitch M.I. & Warner E. (1997) Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology 15, 110-115.
9. Pazdur R., Douillard J.-Y., Skillings J.R. & Eisenberg P.D. (1999) Multicenter phase II study of 5-fluorouracil or UFT™ in combination with leucovorin in patients with metastatic colorectal cancer. Proceedings of the American Society of Clinical Oncology Abstract 1009.
10. Pazdur R., Lassere Y., Rhodes V., Ajani J.A., Sugarman S.M., Patt Y.Z., Jones D.V. Jr, Markowitz A.B., Abbruzzese J.L. & Bready B. (1994) Phase II trial of uracil and tegafur plus oral leucovorin; an effective oral regimen in the treatment of metastatic colorectal carcinoma. Journal of Clinical Oncology 12, 2296-2300.
11. Poon M.A., O'Connell M.J., Moertel C.G., Wieand H.S., Cullinan S.A., Everson L.K., Krook J.E., Maillard J.A., Laurie J.A. & Tschetter L.K. (1990) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. Journal of Clinical Oncology 8, 313-316.
12. Therasse P., Arburck S., Eisenhauer E., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., van Glabbeke M., van Oosterom A.J., Christian M.C. & Gwyther S.G. (2000) New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 92, 205-216.
13. Wolmark N., Rockette H., Mamounas E., Jones J., Wieand S., Wickerham D.L., Bear H.D., Atkins J.N., Dimitrov N.V., Glass A.G., Fisher E.R. & Fisher B. (1999) Clinical trial to assess the relative efficacy of fluorouracil and levamisole, fluorouracil and leucovorin and fluorouracil, leucovorin and levamisole in patients with Dukes B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C04. Journal of Clinical Oncology 17, 3553-3559.